Abiopharma

🔍 Murray Jason Hulse (Director)

Company: PACS Group, Inc. (PACS)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Sold 9,758 shares of Common Stock at $43.3416 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,071,774.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 74,844 shares of Common Stock at $44.2704 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 54,996,930.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 66,797 shares of Common Stock at $44.1807 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 54,930,133.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 84,650 shares of Common Stock at $44.2645 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 54,845,483.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 67 shares of Common Stock at $44.8472 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 54,845,416.00 | transaction_form_type: 4 | Footnotes: F1, F6

Footnotes:

• F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
• F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $42.805 to $43.8025 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $43.81 to $44.51 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $43.81 to $44.67 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $43.84 to $44.80 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $44.845 to $44.86 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.